Owen A Williams1,2, Yang An1, Nicole M Armstrong1, Melissa Kitner-Triolo1, Luigi Ferrucci3, Susan M Resnick1. 1. Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, MD, USA. 2. Department of Experimental Psychology, University of Oxford, Oxford, UK. 3. Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, Baltimore, MD, USA.
Abstract
BACKGROUND: Alzheimer's disease (AD) is now understood to have a long preclinical phase in which pathology starts to accumulate in the absence of clinical symptoms. Identifying the temporal stages of accelerated cognitive decline in this phase may help in developing more sensitive neuropsychological tools for early screening of preclinical cognitive decline. Change-point analyses are increasingly used to characterize the temporal stages of accelerated cognitive decline in the preclinical stages of AD. However, statistical comparisons of change-points between specific cognitive measures have not been reported. OBJECTIVE: To characterize and compare the temporal stages of accelerated decline in performance on multiple cognitive tests in a sample of participants from the Baltimore Longitudinal Study on Aging (BLSA) who later developed AD. METHODS: 165 older adults (baseline age range: 61.1-91.2) from the BLSA developed AD during follow-up. Linear and non-linear mixed models were fit for 11 cognitive measures to determine change-points in rates of decline before AD diagnosis. Bootstrapping was used to compare the timing of change-points across cognitive measures. RESULTS: Change-points followed by accelerated decline ranged from 15.5 years (Standard Error (S.E.) = 1.72) for Card Rotations to 1.9 years (S.E. = 0.68) for the Trail-Making Test Part A before AD diagnosis. Accelerated decline in Card Rotations occurred significantly earlier than all other measures, including learning and memory measures. CONCLUSION: Results suggest that visuospatial ability, as assessed by Card Rotations, may have the greatest utility as an early predictive tool in identifying preclinical AD.
BACKGROUND:Alzheimer's disease (AD) is now understood to have a long preclinical phase in which pathology starts to accumulate in the absence of clinical symptoms. Identifying the temporal stages of accelerated cognitive decline in this phase may help in developing more sensitive neuropsychological tools for early screening of preclinical cognitive decline. Change-point analyses are increasingly used to characterize the temporal stages of accelerated cognitive decline in the preclinical stages of AD. However, statistical comparisons of change-points between specific cognitive measures have not been reported. OBJECTIVE: To characterize and compare the temporal stages of accelerated decline in performance on multiple cognitive tests in a sample of participants from the Baltimore Longitudinal Study on Aging (BLSA) who later developed AD. METHODS: 165 older adults (baseline age range: 61.1-91.2) from the BLSA developed AD during follow-up. Linear and non-linear mixed models were fit for 11 cognitive measures to determine change-points in rates of decline before AD diagnosis. Bootstrapping was used to compare the timing of change-points across cognitive measures. RESULTS: Change-points followed by accelerated decline ranged from 15.5 years (Standard Error (S.E.) = 1.72) for Card Rotations to 1.9 years (S.E. = 0.68) for the Trail-Making Test Part A before AD diagnosis. Accelerated decline in Card Rotations occurred significantly earlier than all other measures, including learning and memory measures. CONCLUSION: Results suggest that visuospatial ability, as assessed by Card Rotations, may have the greatest utility as an early predictive tool in identifying preclinical AD.
Authors: K M Rodrigue; K M Kennedy; M D Devous; J R Rieck; A C Hebrank; R Diaz-Arrastia; D Mathews; D C Park Journal: Neurology Date: 2012-02-01 Impact factor: 9.910
Authors: Jeff Sevigny; Ping Chiao; Thierry Bussière; Paul H Weinreb; Leslie Williams; Marcel Maier; Robert Dunstan; Stephen Salloway; Tianle Chen; Yan Ling; John O'Gorman; Fang Qian; Mahin Arastu; Mingwei Li; Sowmya Chollate; Melanie S Brennan; Omar Quintero-Monzon; Robert H Scannevin; H Moore Arnold; Thomas Engber; Kenneth Rhodes; James Ferrero; Yaming Hang; Alvydas Mikulskis; Jan Grimm; Christoph Hock; Roger M Nitsch; Alfred Sandrock Journal: Nature Date: 2016-09-01 Impact factor: 49.962
Authors: J Saxton; O L Lopez; G Ratcliff; C Dulberg; L P Fried; M C Carlson; A B Newman; L Kuller Journal: Neurology Date: 2004-12-28 Impact factor: 9.910
Authors: Yu-Ling Chang; Mark W Bondi; Christine Fennema-Notestine; Linda K McEvoy; Donald J Hagler; Mark W Jacobson; Anders M Dale Journal: Neuropsychologia Date: 2009-12-23 Impact factor: 3.139
Authors: Andrea T Shafer; Owen A Williams; Evian Perez; Yang An; Bennett A Landman; Luigi Ferrucci; Susan M Resnick Journal: Brain Commun Date: 2022-03-01
Authors: Yuhai Zhao; Vivian Jaber; Peter N Alexandrov; Andrea Vergallo; Simone Lista; Harald Hampel; Walter J Lukiw Journal: Front Neurosci Date: 2020-10-30 Impact factor: 4.677